FINANCIAL INFORMATION

arrangement. In the case of the Celgene arrangement, we also receive research and development
reimbursement revenue for the clinical trials that Celgene opts into, which are recognized as revenue
over time, as the related research and development services are performed. See Note 3 to the
Accountant’s Report in Appendix I to this prospectus for a description of these agreements.

Expenses

Cost of Revenue

Cost of revenue includes the acquisition costs of our commercial products.

Research and Development Expenses

Research and development expenses consist of the costs associated with our research and
trials and activities related to

development activities, conducting preclinical studies and clinical
regulatory filings. Our research and development expenses consist of:

•

•

•

•

•

•

expenses incurred under agreements with CROs, contract manufacturing organizations, and
consultants that conduct and support clinical trials and preclinical studies;

costs of comparator drugs in certain of our clinical trials;

costs associated with preclinical activities and development activities;

costs associated with regulatory operations;

employee-related
compensation expense for research and development personnel; and

expenses,

benefits,

including

salaries,

travel

and

share-based

other expenses, which include direct and allocated expenses for rent and maintenance of
facilities, insurance and other supplies used in research and development activities.

Our current research and development activities mainly relate to the clinical advancement of our

six internally-developed drug candidates mentioned below:

•

•

•

•

•

zanubrutinib, an investigational small molecule inhibitor of BTK;

tislelizumab, an investigational humanized monoclonal antibody against PD-1;

pamiparib, an investigational small molecule inhibitor of PARP1 and PARP2;

lifirafenib, a novel small molecule inhibitor of both the monomer and dimer forms of
BRAF;

BGB-A333, an investigational humanized monoclonal antibody against PD-L1; and

— 262 —

